drugset / Trial / NCT00448409
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.
Timeline
- Start
- 2006-05
- Primary completion
- 2007-04
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TroVax | Vaccine | 5e+08 unknown | Intramuscular |
| Subject | sargramostim | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |